An anti-cancer drug from a new class of agents called selective endothelin-A receptor antagonists, this drug is being studied in a subset of patients with advanced prostate cancer.
Phase II and III studies evaluating time to clinical and radiographic progression failed to demonstrate a significant benefit with atrasentan versus placebo.
The adverse effects, observed more frequently in those treated with atrasentan than in placebo-treated patients, included peripheral edema, rhinitis, headache, infection, dyspnea, and heart failure.
Atrasentan's role in the various stages of advanced prostate cancer, and relative to the chemotherapeutic agent docetaxel, has not been determined.